About HEARTCARE-B Company

Shanghai Xinwei Medical Technology Co., Ltd. (stock code: 06609.HK) was established in 2016. The company is committed to improving the accessibility of innovative medical technology and protecting life and health. In six years, Xinwei Medical pioneered the first one-stop solution for stroke treatment and prevention in the field of neurological intervention. It has a full product pipeline from acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment to interventional access devices, and has applied for more than 200 patents, and its sales channels cover all provinces in China other than Hong Kong, China, Macau, and Taiwan. Based on its existing leading edge, Xinwei Medical will continue to focus on popularizing emerging medical procedures, focusing on the unmet needs of clinicians and patients in mainland China, and operating multiple emerging business segments including neurological intervention, whole-heart treatment, pulmonary intervention, and computer-assisted technology. It looks forward to continuously introducing innovative interventional devices defining emerging procedures in these medical fields with huge potential to reduce mortality from major diseases and improve patient outcomes.